Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 12/2010

01-12-2010 | Original paper

Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case–control study

Authors: Emily J. Fearnley, Louise Marquart, Amanda B. Spurdle, Philip Weinstein, Penelope M. Webb, The Australian Ovarian Cancer Study Group and The Australian National Endometrial Cancer Study Group

Published in: Cancer Causes & Control | Issue 12/2010

Login to get access

Abstract

Objective

Although polycystic ovary syndrome (PCOS) is commonly cited as a risk factor for endometrial cancer, supporting epidemiological evidence is currently very limited. Our aim was to assess the associations between PCOS, PCOS symptoms, and risk of endometrial cancer in women aged less than 50 years.

Methods

Data came from a national population-based case–control study in Australia. Cases with newly diagnosed histologically confirmed endometrial cancer were identified through treatment clinics and cancer registries Australia wide. Controls were randomly selected from the national electoral roll. Women were interviewed about their reproductive and medical history, including self-reported PCOS, and lifestyle. Current analyses were restricted to women aged under 50 (156 cases, 398 controls). We estimated odds ratios (OR) using logistic regression to adjust for confounding factors.

Results

Women with PCOS had a fourfold increased risk of endometrial cancer compared to women without PCOS (OR 4.0, 95% CI 1.7–9.3). This association was attenuated when additionally adjusted for body mass index (OR 2.2, 95% CI 0.9–5.7). Risk was slightly greater when restricted to Type I cancers. PCOS symptoms including hirsutism and very irregular periods were significantly associated with endometrial cancer risk.

Conclusions

These data extend existing findings, including adjustment for confounders, suggesting PCOS is a risk factor for endometrial cancer.
Appendix
Available only for authorised users
Literature
1.
Sankaranarayanan R, Ferlay J (2006) Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 20(2):207–225CrossRefPubMed
2.
Wild S, Pierpoint T, Jacobs H, McKeigue P (2000) Long-term consequences of polycystic ovary syndrome: results of a 31 year follow up study. Hum Fertil 3:101–105CrossRef
3.
Hardiman P, Pillay OC, Atiomo W (2003) Polycystic ovary syndrome and endometrial carcinoma. Lancet 361(9371):1810–1812CrossRefPubMed
4.
Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS (2006) Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 91(4):1357–1363CrossRefPubMed
5.
Michelmore KF, Balen AH, Dunger DB, Vessey MP (1999) Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol 51:779–786CrossRef
6.
Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected caucasian women from Spain. J Clin Endocrinol Metab 85(7):2434–2438CrossRefPubMed
7.
Azziz R, Woods K, Reyna R, Key T, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89(6):2745–2749CrossRefPubMed
8.
Speert H (1949) Carcinoma of the endometrium in young women. Surg Gynaecol Obstet 88:332–336
9.
Dockerty MB, Loveday SB, Foust GT (1951) Carcinoma of the corpus uteri in young women. Am J Obstet Gynecol 61:966–981PubMed
10.
Jackson R, Dockerty MB (1957) The Stein–Leventhal syndrome: analysis of 43 cases with special reference to association with endometrial carcinoma. Am J Obstet Gynecol 73:161–173PubMed
11.
Elliott JL, Hosford SL, Demopoulos RI, Perloe M, Sills ES (2001) Endometrial adenocarcinoma and polycystic ovary syndrome: Risk factors, management, and prognosis. South Med J 94(5):529–531PubMed
12.
Jafari K, Javaheri G, Ruiz G (1978) Endometrial adenocarcinoma and the Stein-Leventhal syndrome. Obstet Gynecol 51:97–100PubMed
13.
Gallup D, Stock R (1984) Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 64:417–420PubMed
14.
Escobedo LG, Lee N, Peterson H, Wingo P (1991) Infertility associated endometrial cancer risk may be limited to specific subgroups in infertile women. Obstet Gynecol 77:124–128PubMed
15.
Coulam C, Annegers J, Kranz J (1983) Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 61:403–407PubMed
16.
Iatrakis G, Zervoudis S, Saviolakis A et al (2006) Women younger than 50 years with endometrial cancer. Eur J Gynaecol Oncol 27(4):399–400PubMed
17.
Niwa K, Imai A, Hashimoto M et al (2000) A case–control study of uterine endometrial cancer of pre- and post-menopausal women. Oncology Rep 7(1):89–93
18.
Pillay OC, Te Fong LFW, Crow JC et al (2006) The association between polycystic ovaries and endometrial cancer. Hum Reprod 21(4):924–929CrossRefPubMed
19.
Fader AN, Arriba LN, Frasure HE, von Gruenigen VE (2009) Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 114(1):121–127CrossRefPubMed
20.
Pasquali R, Casimirri F (1993) The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 39:1–16CrossRef
21.
Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122(1):170–176CrossRefPubMed
22.
23.
Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2005) Endometrial cancer. Lancet 366:491–505CrossRefPubMed
24.
Navaratnarajah R, Pillay OC, Hardiman P (2008) Polycystic ovary syndrome and endometrial cancer. Semin Reprod Med 26(1):62–71CrossRefPubMed
25.
Chittenden B, Fullerton G, Maheshawari A, Bhattacharya S (2009) Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 19(3):398–405CrossRefPubMed
26.
Dahlgren E, Friberg LG, Johansson S et al (1991) Endometrial carcinoma; ovarian dysfunction - a risk factor in young women. Eur J Obstet Gynecol Reprod Biol 41:143–150CrossRefPubMed
27.
Balen AH, Conway GS, Kaltsas G et al (1995) Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 10(8):2107–2111PubMed
28.
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19(1):41–47CrossRef
29.
Jordan SJ, Green AC, Whiteman DC, Moore SP, Bain CJ, Gertig DM (2008) Serous ovarian, fallopian tube and primary peritoneal cancers: A comparative epidemiological analysis. Int J Cancer 122:1598–1603CrossRefPubMed
Metadata
Title
Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case–control study
Authors
Emily J. Fearnley
Louise Marquart
Amanda B. Spurdle
Philip Weinstein
Penelope M. Webb
The Australian Ovarian Cancer Study Group and The Australian National Endometrial Cancer Study Group
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 12/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9658-7

Other articles of this Issue 12/2010

Cancer Causes & Control 12/2010 Go to the issue

Original paper

Exogenous sex hormone use and risk of meningioma: a population-based case–control study in Finland

Original paper

Iron intake and markers of iron status and risk of Barrett’s esophagus and esophageal adenocarcinoma

Original paper

Urinary phytoestrogens and risk of prostate cancer in Jamaican men

Original paper

Australian women’s awareness of ovarian cancer symptoms, risk and protective factors, and estimates of own risk

Original paper

Recreational physical activity, anthropometric factors, and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women

Original paper

Physical activity, body size and composition, and risk of ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits